Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant

Read full release

Laevoroc Oncology Announces Publication Identifying Purine Nucleoside Phosphorylase (PNP) as Novel Metabolic Immune Checkpoint

Read full release

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia

Read full release

Laevoroc Oncology Emerges from Stealth Mode Announcing Seed Financing and Acquisition of Worldwide Patents to Oral Gemcitabine Prodrug

Read full release